Poseida Therapeutics, Inc.

We’re excited to highlight our interim Phase 1 data from lead #allogeneic #CART program, P-BCMA-ALLO1, targeting multiple myeloma, alongside preclinical updates on P-CD19CD20-ALLO1 for B-cell malignancies. Don’t miss all the details at #ASH24! https://lnkd.in/e-S-tFeJ #CapacitytoCure #celltherapy

We’re thrilled to announce Poseida entered into a definitive agreement to be acquired by Roche Holdings, Inc. At the closing of the proposed transaction, Poseida and its employees will join the Roche Group and advance our innovative pipeline of non-viral, Tscm-rich CAR-T therapies and genetic medicines as part of Roche’s Pharmaceuticals Division. Details here: https://lnkd.in/gvbwFU7r #CapacitytoCure #celltherapy #CART #geneticmedicines

Learn more about our CEO, Kristin Yarema, Ph.D., her career in #biotech and her vision for the future of #allogeneic cell therapy and non-viral genetic medicines. All this and more in Biotech2050’s latest podcast out now: https://lnkd.in/dbXeNNn2 #CapacitytoCure #celltherapy #CART

Join us at our November A2I Coffee Club on November 21 from 6:30pm-7:30pm on Zoom! This time we will focus on the Science and Scope of CAR T-cell Therapy with two specialists from Poseida Therapeutics! Register at https://lnkd.in/gnyfbSpU or by scanning QR code on flyer. Visit AWIS.org for membership details and email [email protected] for more meeting info.

Tune into CGTLive’s latest interview with Bhagirathbhai Dholaria, MD, discussing Poseida’s #IMS2024 data on P-BCMA-ALLO1 in multiple myeloma: https://lnkd.in/eXCF_GcC

Our CEO, Kristin Yarema, Ph.D., will be providing a corporate presentation at Stifel’s 2024 Healthcare Conference on Monday, November 18. The presentation will be webcast live on our website at https://lnkd.in/euY5mmFc, with a replay available shortly thereafter. #CapacitytoCure #celltherapy #geneticmedicines

Poseida is going live at 10 am ET. Join our exciting #celltherapy R&D Day, where we’ll share the latest on our clinical and early-stage cell therapy programs targeting #oncology and #autoimmune disease: https://lnkd.in/e9a5C_eJ    More details in today’s news: https://lnkd.in/esP6E_Uh   #CapacitytoCure #allogeneic #CART

We are so proud to be recognized as a BioSpace Best Place to Work for the second year in a row! A big thanks to our dedicated, passionate, and patient-centric team for all their hard work and earning this recognition. More on what makes us a #bestplacetowork: https://lnkd.in/e5AC_YG7 #CapacitytoCure #PoseidaProud

Honoring the brave men and women who have served in the military today and every day. Your courage, sacrifice, and commitment to our nation inspires us all. Thank you for your service. #PoseidaProud #HonoringHeroes #CapacitytoCure 

#CellandGeneTherapies are transforming our approach to treating disease, offering more precise disease-modifying and, in some cases, potentially curative solutions that give new hope to patients. This potential was evident when I attended #CGMesa24 recently, where scientific progress in the field took the spotlight and stories highlighting the impact on patients served as a powerful reminder of why our efforts matter and the power innovation holds to change lives.   I was delighted to join a fireside chat with Kristin Yarema, Ph.D., President and CEO of Poseida Therapeutics – one of our key innovation partners in cell therapy – to discuss the advances Astellas is making in cell and gene therapy.   In addition, my colleagues Richard Wilson, Primary Focus Lead, Genetic Regulation, and Ha Tran, MD, MS, Head of Medical Development, Cell and Gene Therapy, shared their expertise during the meeting, addressing critical challenges and opportunities in the field alongside updates on our work in cell and gene therapy.   A few key insights from the event that resonated with me: New approvals are rapidly advancing. We’ve seen a number of high profile approvals in areas such as advanced synovial sarcoma and Hemophilia B, and up to 14 cell and gene therapy approvals are expected this year across the US and EU – signaling positive momentum toward the FDA’s goal of 10 to 20 approvals per year starting in 2025. After seeing somewhat of a slowdown in 2022 and 2023, investment in cell and gene therapy is resurging. Strong clinical data and positive real-world evidence are supporting investor confidence, particularly in late-stage assets, setting the stage for further innovation and growth. Manufacturing remains a significant challenge to ensuring these innovative therapies reach patients in need. Manufacturing methods vary depending on the type of therapy and cell source, with differing levels of complexity. Navigating this complexity requires substantial and early investment to standardize protocols and build the infrastructure needed to enable scaling up.   Taken together, these insights highlight the significant progress we’re making, but they also underscore the work ahead. I’m proud to be leading a team at Astellas Pharma who shares this commitment to bringing transformative therapies to patients in need.   #ScienceFirstForPatients #ChangingTomorrow